Supercharged immune cells take on Hard-to-Treat myeloma
NCT ID NCT06066359
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests a new approach for people with multiple myeloma that has come back or not responded to treatment. Doctors take immune cells from donated cord blood, genetically engineer them to better recognize and attack myeloma cells, and give them back to the patient along with chemotherapy. The study aims to find the safest dose and see if the cells can control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cord blood-derived natural killer cells genetically engineered with NY-ESO-1 TCR/IL-15, given with chemotherapy drugs fludarabine and cyclophosphamide
What this could lead to
If successful, this could provide a new treatment option for patients with multiple myeloma that has stopped responding to standard therapies.
What could go wrong
This is an early-phase trial with only 44 participants, so the treatment may not work for everyone and could cause serious side effects. The cells are experimental and long-term benefits are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact